|
Actos ® Injury Attorneys / Lawyers: Actos® (pioglitazone, also marketed and sold in the United States as Actoplus Met®, and Duetact®) is a newer drug of the class thiazolidinedione. We are particularly interested in speaking to you if you or a loved one have taken Actos® or a related drug and suffered: ·         Bladder Cancer ·         Heart Attack / Stroke ·         Heart Failure ·         Other irregular Cancers or Heart Related Health Issues Facts about pioglitazone: Pioglitazone is sold as a single-ingredient medication / drug under the brand-name Actos®.   This drug product is also sold in combination with metformin, (Actoplus Met®, Actoplus Met XR®) and glimepiride (Duetact®). This drug is used along with diet and exercise to improve control of blood sugar in adults with type 2 diabetes mellitus. Millions of patients have filled prescriptions for a pioglitazone-containing drug from outpatient retail pharmacies.
In August, 2007, the FDA issued an alert highlighting important revisions to the prescribing information for Actos®, including a new boxed warning and revisions to the warnings, precautions, and contraindications.Â
There are many side effects associated with the use of Actos®. Adverse effects for which immediate medical attention should be sought include, but are not limited to: ·       chest tightness or pain
·       irregular breathing, troubled breathing, or shortness of breath ·       wheezing ·       extreme fatigue ·       irregular heartbeat ·       dilated neck veins ·       swelling of face, fingers, feet, or lower legs ·       decreased urine output ·       dental problems / problems with teeth ·       weight gain The above issues primarily relate to potential side effects of this drug that may involve cardiovascular health issues. On June 9, 2011 the French Agency for the Safety of Health Products noted this drug’s high risk of bladder cancer. On June 10th, 2011 Germany's Federal Institute for Drugs and Medical Devices also warned doctors not to prescribe the medication until further investigation of the cancer risk had been completed. On June 15, 2011 the U.S. FDA announced that pioglitazone use for more than one year may be associated with an increased risk of bladder cancer.  The FDA further stated that the information about this risk will be added to the Warnings and Precautions section of the label for pioglitazone-containing medications. The patient Medication Guide for these medicines will also be revised to include information on the risk of bladder cancer. We are particularly interested in speaking to you if you or a loved one have been diagnosed with Bladder Cancer, a Heart Attack, Heart Failure, and/or suffered a Stroke after taking Actos®. If you or a loved one has been injured or is deceased as a result of taking Actos ® or another diabetes medication, you may be entitled to compensation.Â
Contact a pharmaceutical injury lawyer / attorney for a free evaluation of your case.  We would like to hear from you as soon as possible. Delay may cause you to lose your legal rights forever due to the applicable statute of limitations for your area.
Never stop taking any medication without consultation with your physician; Â always follow carefully the directions of your licensed physician.Â
  The Defective Drug Litigation Lawyers at The Mulligan Law Firm are evaluating potential claims for Actos lawsuits related to Bladder Cancer, Heart Attacks, and other issues.  We are evaluating potential claims regardless of the location of the potential plaintiffs in any of the 50 United States.  If you or a loved one have taken Actos or related medications and shown serious side effects such as Bladder Cancer or a Heart Attack, you should call us immediately or fill out one of the forms on this website.  You may be entitled to compensation for your injuries and failure to act quickly may cause you to lose your legal rights forever if the statue of limitations expires.
We are also accepting potential referrals of Actos and other drug injury claims from other attorneys. Â
Contact DrugRxRecall's affiliated attorneys now at 1-888-446-8087, or simply fill out any of the forms on this website. Who We Are
The Mulligan Law Firm, a national law firm located in Dallas, Texas, provides legal information and resources for injured individuals and their families. The firm has successfully resolved over $600,000,000 in claims for its clients. Formed in 1995, it has been helping people for almost 15 years, with the strength and experience to represent plaintiffs in all 50 states.
The Mulligan Law Firm is currently investigating injury claims involving Actos® Bladder Cancer and other injuries from Actos®.Â
If you or a loved one has been seriously injured after taking Actos®, it is important that you consult with a legal professional immediately. The Mulligan Law Firm has lawyers standing by to help you.
You may be entitled to compensation for your injuries. We take all cases on a contingency-fee basis, which means you do not pay for our services unless you receive an award or compensation.
Do not delay, as your rights and compensation may be lost forever if you wait. Statutes of limitations vary by state, and failure to act immediately may cause you to lose your potential legal rights forever.
Â
We thank Wikipedia for the information below and encourage you to support their work. Please see main article, Discussion Tab, Contributors List, and licensing information on this article here:  http://en.wikipedia.org/wiki/Actos
Wikipedia, on Actos:
Pioglitazone From Wikipedia, the free encyclopedia  (Redirected from Actos) Pioglitazone
Systematic (IUPAC) name (RS)-5-(4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl)thiazolidine-2,4-dione Clinical data Trade names Actos AHFS/Drugs.com monograph MedlinePlus a699016 Licence data EMA:Link, US FDA:link Pregnancy cat. C Legal status POM (UK) ℞-only (US) Routes oral Pharmacokinetic data Protein binding >99% Metabolism liver (CYP2C8) Half-life 3–7 hours Excretion in bile Identifiers CAS number 111025-46-8 ATC code A10BG03 PubChem CID 4829 DrugBank APRD00653 ChemSpider 4663 UNII X4OV71U42S KEGG D08378 ChEBI CHEBI:8228 ChEMBL CHEMBL595 Chemical data Formula C19H20N2O3S Mol. mass 356.44 g/mol SMILES eMolecules & PubChem InChI[show]  (what is this?)  (verify) Pioglitazone is a prescription drug of the class thiazolidinedione (TZD) with hypoglycemic (antihyperglycemic, antidiabetic) action. Pioglitazone is marketed as trademarks Actos in the USA, the UK and Germany, Glustin in Europe,"Glizone" and "Pioz" in India by Zydus CND and USV respectively and Zactos in Mexico by Takeda Pharmaceuticals. Actos was the tenth-best selling drug in the U.S. in 2008, with sales exceeding $2.4 billion.[1] Its cardiovascular safety profile compares favorably with rosiglitazone (Avandia), which was withdrawn after concerns about an increased risk of cardiac events, but pioglitazone has subsequently been found to be associated with bladder tumors and has been withdrawn in some countries. Contents 1 Pharmacology 2 Indications and usage 3 Contraindication 4 Side effects 5 Drug interactions 6 Formulations 7 References 8 External links  Pharmacology
Pioglitazone selectively stimulates the nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR-γ) and to a lesser extent PPAR-α.[2][3] It modulates the transcription of the insulin-sensitive genes involved in the control of glucose and lipid metabolism in the muscle, adipose tissue, and the liver. As a result, pioglitazone reduces insulin resistance in the liver and peripheral tissues; increases the expense of insulin-dependent glucose; decreases withdrawal of glucose from the liver; reduces quantity of glucose, insulin and glycated hemoglobin in the bloodstream. Although not clinically significant, pioglitazone decreases the level of triglycerides and increases that of high-density lipoproteins (HDL) without changing low-density lipoproteins (LDL) and total cholesterol in patients with disorders of lipid metabolism, although statins are the drug of choice for this. More recently,[when?] pioglitazone and other active TZDs have been shown to bind to the outer mitochondrial membrane protein mitoNEET with affinity comparable to that of pioglitazone for PPARγ.[4][5]  Indications and usage
Pioglitazone is used for the treatment of diabetes mellitus type 2 (previously known as non-insulin-dependent diabetes mellitus, NIDDM) in monotherapy and in combination with a sulfonylurea, metformin, or insulin. Pioglitazone has also been used to treat non-alcoholic steatohepatitis (fatty liver), but this use is presently considered experimental.[6] Pioglitazone has also been found to reduce the risk of conversion from prediabetes to diabetes mellitus type 2 by 72%. [7] Â Contraindication
This section does not cite any references or sources. Please help improve this section by adding citations to reliable sources. Unsourced material may be challenged and removed. (March 2011) Pioglitazone cannot be used in patients with a known hypersensitivity to pioglitazone, other thiazolidinediones or any of components of its pharmaceutical forms. It is ineffective and possibly harmful in diabetes mellitus type 1 and diabetic ketoacidosis. Its safety in pregnancy, lactation (breastfeeding) and people under 18 is not established. Given previous experiences with the related drug troglitazone, acute diseases of the liver are regarded as a contraindication for pioglitazone. Pioglitazone and all other drugs of its class (Thiazolidinediones) are absolutely contraindicated in patients with Heart Failure. Â Side effects
A press release by GlaxoSmithKline in February 2007 noted that there is a greater incidence of fractures of the upper arms, hands and feet in female diabetics given rosiglitazone compared with those given metformin or glyburide. The information was based on data from the ADOPT trial. Following release of this statement, Takeda also admitted that pioglitazone has similar implications for female patients.[citation needed] The risk of hypoglycemia is low in the absence of other drugs that lower blood glucose. Pioglitazone can cause fluid retention and peripheral edema. As a result, it may precipitate congestive heart failure (which worsens with fluid overload in those at risk). It may cause anemia. Mild weight gain is common due to increase in subcutaneous adipose tissue. In studies, patients on pioglitazone had an increased proportion of upper respiratory tract infection, sinusitis, headache, myalgia and tooth problems. On July 30, 2007 an Advisory Committee of the Food and Drug Administration concluded that the use of rosiglitazone for the treatment of type 2 diabetes was associated with a greater risk of "myocardial ischemic events" when compared to placebo, but when compared to other diabetes drugs, there was no increased risk. Pioglitazone is currently being reviewed. A meta-analysis released subsequently showed that pioglitazone reduced the number of ischemic cardiac events rather than increase the risk, but increases CHF.[8] The PERISCOPE study compared pioglitazone with glimepiride in diabetics; atherosclerotic plaque volume was measured and followed over time. Glimepiride therapy had highly significant progression of plaque volume over time of 0.73 percent. In comparison, pioglitazone had a -0.16 percent regression in plaque volume. This is the first study to show that diabetic therapy slowed progression of atherosclerosis. Therapy with pioglitazone raised HDL, and lowered triglyceride and hsCRP; these are all beneficial effects on risk factors for coronary artery disease, however to date, no oral anti-diabetic drug has been shown to reduce the risk of cardiovascular complications.[9] Chronic administration of the drug has led to occasional instances of cholestatic hepatitis, reversible upon drug discontinuation.[10]
On June 9, 2011 the French Agency for the Safety of Health Products has decided to pull out the market this molecule in regards to high risk of bladder cancer [11] On June 10th, 2011 Germany's Federal Institute for Drugs and Medical Devices also advised doctors not to prescribe the medication until further investigation of the cancer risk had been conducted.[12] On June 15, 2011 the U.S. FDA announced that pioglitazone use for more than one year may be associated with an increased risk of bladder cancer, and that the information about this risk will be added to the Warnings and Precautions section of the label for pioglitazone-containing medicines. The patient Medication Guide for these medicines will also be revised to include information on the risk of bladder cancer.[13] Â Drug interactions
This section does not cite any references or sources. Please help improve this section by adding citations to reliable sources. Unsourced material may be challenged and removed. (March 2011) Sulfonamides, metformin, and insulin reciprocally exponentiate hypoglycemia. Therapy with pioglitazone increased risk for pregnancy in those taking oral contraception. Â Formulations
This section does not cite any references or sources. Please help improve this section by adding citations to reliable sources. Unsourced material may be challenged and removed. (March 2011) Pioglitazone as Actos is supplied in oral tablets containing 15, 30 or 45 mg of pioglitazone base. It is also available in combination with metformin as ActoplusMet (tablets containing 15 mg pioglitazone and either 500 or 850 mg of metformin), Competact (tablets containing 15 mg pioglitazone and 850 mg of metformin) or in combination with glimepiride as Duetact (tablets containing 30 mg pioglitazone and either 2 or 4 mg of glimepiride). Â References
^ Details for Actos. ^ Gillies, PS; Dunn, CJ (August 2000). "Pioglitazone". Drugs 60 (2): 333–43; discussion 344–5. doi:10.2165/00003495-200060020-00009. PMID 10983737. ^ Smith U (September 2001). "Pioglitazone: mechanism of action". Int J Clin Pract Suppl (121): 13–8. PMID 11594239. ^ Colca, JR; McDonald, WG; Waldon, DJ; Leone, JW; Lull, JM; Bannow, CA; Lund, ET; Mathews, WR (February 2004). "Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe". Am. J. Physiol. Endocrinol. Metab. 286 (2): E252–60. doi:10.1152/ajpendo.00424.2003. PMID 14570702. ^ Paddock, ML; Wiley, SE; Axelrod, HL; Cohen, AE; Roy, M; Abresch, EC; Capraro, D; Murphy, AN et al. (September 2007). "MitoNEET is a uniquely folded 2Fe 2S outer mitochondrial membrane protein stabilized by pioglitazone". Proc. Natl. Acad. Sci. U.S.A. 104 (36): 14342–7. doi:10.1073/pnas.0707189104. PMC 1963346. PMID 17766440. ^ Belfort, R; Harrison, SA; Brown, K; Darland, C; Finch, J; Hardies, J; Balas, B; Gastaldelli, A et al. (November 2006). "A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis". N. Engl. J. Med. 355 (22): 2297–307. doi:10.1056/NEJMoa060326. PMID 17135584. ^ DeFronzo, Ralph A.. "Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance". N Eng J Med 2011; 364: 1104-1115. Retrieved March 29, 2011. ^ Lincoff AM, Wolski K, Nicholls SJ, Nissen SE (2007). "Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials". JAMA 298 (10): 1180–8. doi:10.1001/jama.298.10.1180. PMID 17848652. ^ Nissen SE, Nicholls SJ, Wolski K (2008). "Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes". JAMA 299 (13): 1561. doi:10.1001/jama.299.13.1561. PMID 18378631. ^ R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 1271-1272. ^ http://www.lefigaro.fr/flash-actu/2011/06/09/97001-20110609FILWWW00505-info-le-figaro-lantidiabetique-actos-retire-du-marche.php. ^ http://www.reuters.com/article/2011/06/10/takeda-germany-idUSL3E7HA0X920110610. ^ http://www.fda.gov/Drugs/DrugSafety/ucm259150.htm | FDA Drug Safety Communication: Update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer|.  External links
Official site Pioglitazone FAQ U.S. National Library of Medicine: Drug Information Portal - Pioglitazonee [hide]v · d · eOral anti-diabetic drugs and Insulin analogs (A10) Insulin Sensitizers Biguanides Metformin# • Buformin‡ • Phenformin‡ TZDs (PPAR) Pioglitazone • Rivoglitazone†• Rosiglitazone • Troglitazone‡ Dual PPAR agonist Aleglitazar†• Muraglitazar§ • Tesaglitazar§ Secretagogues K+ ATP Sulfonylureas 1st generation: Acetohexamide • Carbutamide • Chlorpropamide • Tolbutamide • Tolazamide 2nd generation: Glibenclamide (Glyburide)# • Glipizide • Gliquidone • Glyclopyramide  • Glimepiride  • Gliclazide • Meglitinides/"glinides" Nateglinide • Repaglinide • Mitiglinide GLP-1 analogs Exenatide • Liraglutide • Taspoglutide†• Albiglutide†• Lixisenatide DPP-4 inhibitors Alogliptin†• Linagliptin • Saxagliptin • Sitagliptin • Vildagliptin Analogs/other insulins fast-acting (Insulin lispro • Insulin aspart • Insulin glulisine) • short-acting (Regular insulin) • long-acting (Insulin glargine • Insulin detemir • NPH insulin) • ultra-long-acting (Insulin degludec†) • inhalable Exubera‡ Other Alpha-glucosidase inhibitors Acarbose • Miglitol • Voglibose Amylin analog Pramlintide SGLT2 inhibitors Canagliflozin†• Dapagliflozin†• Remogliflozin§ • Sergliflozin§ Other Benfluorex‡ • Tolrestat‡ #WHO-EM. ‡Withdrawn from market. Clinical trials: †Phase III. §Never to phase III M: END anat/phys/devp/horm noco(d)/cong/tumr, sysi/epon proc, drug (A10/H1/H2/H3/H5) Â
|
